Loading
A phase 3 trial of Odronextamab, Lenalidomide, Rituximab in follicular lymphoma, run by Regeneron Pharmaceuticals, now recruiting.
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma is a phase 3 interventional study registered as NCT06149286 by Regeneron Pharmaceuticals, with 580 participants planned, started 2023-12-28 and due to reach its primary completion in 2031-04-30. Interventions recorded: Odronextamab, Lenalidomide, Rituximab. Conditions listed: Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.
Shares Odronextamab, Regeneron, Rituximab, T-cell engagers (bispecific).
Shares Odronextamab, Regeneron, Rituximab, T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, T-cell engagers (bispecific).
Shares Odronextamab, Regeneron, Rituximab, T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/